Dua, T;
Barbui, C;
Clark, N;
Fleischmann, A;
Poznyak, V;
van Ommeren, M;
Yasamy, MT;
... Saxena, S; + view all
(2011)
Evidence-Based Guidelines for Mental, Neurological, and Substance Use Disorders in Low- and Middle-Income Countries: Summary of WHO Recommendations.
PLOS MEDICINE
, 8
(11)
, Article e1001122. 10.1371/journal.pmed.1001122.
![[thumbnail of 1339567.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/application_pdf.png) Preview |
PDF
1339567.pdf Download (260kB) |
| Type: | Article |
|---|---|
| Title: | Evidence-Based Guidelines for Mental, Neurological, and Substance Use Disorders in Low- and Middle-Income Countries: Summary of WHO Recommendations |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1371/journal.pmed.1001122 |
| Publisher version: | http://dx.doi.org/10.1371/journal.pmed.1001122 |
| Language: | English |
| Additional information: | © 2011 Dua et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Funding: Funding for the mhGAP Programme, under which the work reported in this manuscript was done, was provided by the following: American Psychiatric Foundation, USA; Association of Aichi Psychiatric Hospitals, Japan; Autism Speaks, USA; CBM; Government of Italy; Government of Japan; Government of The Netherlands; International Bureau for Epilepsy; International League Against Epilepsy; Medical Research Council, UK; National Institute of Mental Health, USA; Public Health Agency of Canada, Canada; Rockefeller Foundation, USA; Shirley Foundation, UK; Syngenta, Switzerland; United Nations Population Fund; World Psychiatric Association. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing interests: JLA was paid in 2007 by Lundbeck S.A. for consultancy preparation of the research protocol for a study on the diagnostic delay in first episode of depression in contact with health care centers in Spain and was paid in 2009 by Sanofi Aventis S.A. for expert testimony on the side effects of veralapride. OO is the current President of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP) (http://www.iacapap.org/). JWS served on scientific advisory boards for GlaxoSmithKline (2010), Eisai (2009), and UCB (2009); received funding for travel from UCB (2008) and Janssen (2009); serves on the editorial boards of Lancet Neurology, Epilepsia and Epileptic Disorders; served on the speaker's bureaus of UCB (2009) and GlaxoSmithKline (2009); and has received research support from UCB (grant finished 2010), Eisai (grant finished 2008), the NIH (ongoing grant), the EU FP7 (ongoing grant), the Wellcome Trust (grant finished 2009), WHO (ongoing grant), the National Epilepsy Funds of the Netherlands (ongoing grant), and the Epilepsy Society (ongoing grant). His current position is endowed by the National Society for Epilepsy (UK). SS confirms that the competing interests of JWS were declared, reviewed, and deemed acceptable by the mhGAP Guideline Development Group. All other authors have declared that no competing interests exist. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Clinical and Experimental Epilepsy |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1339567 |
Archive Staff Only
 |
View Item |
